- Stocks
- Healthcare
- NYSE: DNA

Price (delayed)

$7.55

Market cap

$419.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$18.4

Enterprise value

$141.49M

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline

DNA's gross margin is up by 13% year-on-year

The EPS rose by 31% year-on-year but it has declined by 4.5% since the previous quarter

The net income has grown by 27% YoY but it has contracted by 5% from the previous quarter

The debt has soared by 93% since the previous quarter and by 10% year-on-year

The equity is down by 45% year-on-year and by 16% since the previous quarter

What are the main financial stats of DNA

Market
Valuations
Earnings

Shares outstanding

55.58M

Market cap

$419.59M

Enterprise value

$141.49M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.5

Price to sales (P/S)

2.1

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.77

Revenue

$184.34M

EBIT

-$897.58M

EBITDA

-$807.95M

Free cash flow

-$344.91M

Per share
Balance sheet
Liquidity

EPS

-$18.4

Free cash flow per share

-$6.71

Book value per share

$15.07

Revenue per share

$3.59

TBVPS

$29.87

Total assets

$1.63B

Total liabilities

$792.18M

Debt

$452.27M

Equity

$833.07M

Working capital

$617.21M

Debt to equity

0.54

Current ratio

4.71

Quick ratio

4.51

Net debt/EBITDA

0.34

Margins
Efficiency
Dividend

EBITDA margin

-438.3%

Gross margin

80.2%

Net margin

-487%

Operating margin

-469.5%

Return on assets

-52%

Return on equity

-86.1%

Return on invested capital

-103.4%

Return on capital employed

-61.5%

Return on sales

-486.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ginkgo Bioworks Holdings stock price performed over time

Intraday

10.87%

1 week

20.99%

1 month

-14.79%

1 year

-89.8%

YTD

-88.83%

QTD

-43.53%

How have Ginkgo Bioworks Holdings's revenue and profit performed over time

Revenue

$184.34M

Gross profit

$147.88M

Operating income

-$865.46M

Net income

-$897.68M

Gross margin

80.2%

Net margin

-487%

The revenue has declined by 43% year-on-year and by 12% since the previous quarter

The gross profit has declined by 36% year-on-year and by 12% since the previous quarter

DNA's operating income is up by 33% year-on-year but it is down by 4.7% since the previous quarter

The net margin is down by 30% year-on-year and by 19% since the previous quarter

What is Ginkgo Bioworks Holdings's growth rate over time

What is Ginkgo Bioworks Holdings stock price valuation

P/E

N/A

P/B

0.5

P/S

2.1

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

0.77

The EPS rose by 31% year-on-year but it has declined by 4.5% since the previous quarter

The price to book (P/B) is 81% lower than the last 4 quarters average of 2.4

The equity is down by 45% year-on-year and by 16% since the previous quarter

The stock's price to sales (P/S) is 81% less than its last 4 quarters average of 9.8

The revenue has declined by 43% year-on-year and by 12% since the previous quarter

How efficient is Ginkgo Bioworks Holdings business performance

The return on sales has declined by 28% year-on-year and by 19% since the previous quarter

The ROE has contracted by 22% from the previous quarter and by 11% YoY

The company's return on assets fell by 15% QoQ but it rose by 3.2% YoY

The company's return on invested capital rose by 11% YoY but it fell by 11% QoQ

What is DNA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for DNA.

How did Ginkgo Bioworks Holdings financials performed over time

Ginkgo Bioworks Holdings's total assets is 105% higher than its total liabilities

Ginkgo Bioworks Holdings's current ratio has decreased by 37% YoY and by 12% from the previous quarter

DNA's quick ratio is down by 37% year-on-year and by 12% since the previous quarter

The debt is 46% smaller than the equity

The debt to equity has soared by 125% from the previous quarter and by 100% YoY

The debt has soared by 93% since the previous quarter and by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.